ICB have been approved for various types of cancer, including non-small-cell lung cancer, melanoma, and renal cell carcinoma (1–6), and recently also for previously treated advanced gastric cancer with PD-L1 expression (combined positive score (CPS) ≥1) (8, 9). This evidence concerns the gene CD274 and cancer.